Advertisement
Screener

ENSYSCE BIOSCIENCES, INC. (ENSC) Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

2.8 / 5 stars · 68/120 Roast Me

ENSYSCE BIOSCIENCES, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

ENSYSCE BIOSCIENCES, INC. (ENSC) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $741.87 thousand as of 2025-12-31, per its 10-K filed 2026-03-30.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-30

  • 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $741.87K.
  • 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $729.32K.
  • 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $746.44K.
  • 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.17M.
Period endDeferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
2025-12-31$741.87K
10-K · filed 2026-03-30
2024-12-31$729.32K
10-K · filed 2026-03-30
2023-12-31$746.44K
10-K · filed 2025-03-10
2022-12-31$1.17M
10-K · filed 2024-03-15
2021-12-31$915.67K
10-K · filed 2023-03-30
2020-12-31$1.80M
10-K · filed 2022-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
EXICURE, INC. (XCUR)United States$0.008B-1.54
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B
SOLIGENIX, INC. (SNGX)United States$0.008B
Imunon, Inc. (IMNN)United States$0.008B-0.56
Acurx Pharmaceuticals, Inc. (ACXP)United States$0.007B-0.97
SYNLOGIC, INC. (SYBX)United States$0.007B
Traws Pharma, Inc. (TRAW)United States$0.009B-0.58
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26